Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Greten Website

Tim F. Greten, M.D.

Portait Photo of Tim Greten
Thoracic and Gastrointestinal Oncology Branch
Head, Gastrointestinal Malignancy Section
Investigator
Center for Cancer Research
National Cancer Institute
Building 10, Room 12N226
Bethesda, MD 20892
Phone:  
301-451-4723
Fax:  
301-480-8780
E-Mail:  
gretentf@mail.nih.gov

Biography

Tim F. Greten, M.D., received his medical training at Christian Albrechts University in Kiel, Germany in 1993. He did his internship in Munich followed by a three-year postdoctoral fellowship at the Johns Hopkins University Baltimore, in the laboratory of Drew Pardoll and Liz Jaffee, where he initiated his work in the field of tumor immunology. In 1999 Dr. Greten returned to Hannover Medical School, where he finished his training in Internal Medicine (2003), Medical Oncology (2004) and Gastroenterology (2007). He held an associate professor position in the Department of Gastroenterology, Hepatology and Endocrinology. In February 2010 he joined CCR's Medical Oncology Branch as the Program Director of the Gastrointestinal Malignancy Section. Dr. Greten has published more than 70 peer-reviewed papers on basic tumor immunology, translational research studies in hepatocellular carcinoma (HCC) as well as on clinical trials in different gastrointestinal malignancies including HCC. He has also headed the Group for Hepatobiliary Carcinoma from 2006 until 2010 where he has coordinated and directed the German Clinical trial Group (AIO). Currently, Dr. Greten is a member of the NCI Gastrointestinal Malignancy Faculty and Immunology Faculty.

Research

Dr. Greten received his basic research training at the Department of Biochemistry at The Leopold Franzens University Innsbruck Austria, where he was working on DNA repair mechanisms. He received his first postdoctoral training in lab of Stefan Endres at the University of Munich, where he was working on pharmacological inhibition of cytokine production in macrophages and monocytes. In 1995 Dr. Greten received a postdoctoral fellowship by the German Research Association and developed a new method for the identification of antigen-specific CD8+ T cells using MHC-IgG dimeric molecules in the laboratory of Dr. Drew Pardoll and Liz Jaffee in collaboration with Dr. Jonathan Schneck, at Johns Hopkins Medical School, where he also initiated his first studies on the effect of tumor cell death on tumor specific immune responses. Back in Germany Dr. Greten started his own laboratory as a principal investigator at the Medical School in Hannover, Germany in 1999. He received continuous funding from the German Research Association (DFG) as well as the Helmholtz Society and the Association for International Cancer Research (AICR). His major research interest has been the effect of tumor development and tumor-specific treatment on immune response in cancer patients. In addition, his group is interested in identification of tumor suppressor mechanisms with a special focus on new pathways to target these inhibitory mechanisms. His research is currently focused on investigating the role of myeloid derived suppressor cells (MDSC). MDSC occur during acute and chronic inflammation and are potent suppressors of the adaptive and innate immune system. Therefore these cells play an important role in the context of inflammation related tumor development. Dr. Greten's laboratory is currently investigating the role of MDSC, both in murine models of inflammation and cancer as well as in humans with cancer.

This page was last updated on 1/27/2014.